Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application (2018) Zundler S, Dietz L, Matzel KE, Geppert CI, Becker E, Rath T, Neurath M, Atreya R Journal article, Letter SPIONs functionalized with small peptides for binding of lipopolysaccharide, a pathophysiologically relevant microbial product. (2018) Karawacka W, Janko C, Unterweger H, Mühlberger M, Lyer S, Taccardi N, Mokhir A, et al. Journal article Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms (2018) Apostolidis L, Kreutzfeldt S, Oles M, Gieldon L, Heining C, Horak P, Hutter B, et al. Conference contribution COMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET (2018) Pavel ME, Rinke A, Baum RP Conference contribution Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? (2018) Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath M, Zopf Y Journal article, Review article Therapeutic modulation of the bile acid pool by cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice (2018) Chevre R, Trigueros-Motos L, Castano D, Chua T, Corliano M, Patankar J, Sng L, et al. Journal article Interferon-gamma triggers an anti-tumorigenic chain reaction in the tumor vessels of colorectal carcinoma (2018) Stürzl M, Langer V, Regensburger D, Tenkerian C, Klingler A, Waldner M, Becker C, et al. Conference contribution Loss of IFN-gamma pathway gene expression in tumor cells as mechanism of immune escape of colorectal carcinoma (2018) Britzen-Laurent N, Straube J, Waldner M, Becker C, Croner R, Pilarsky C, Merkel S, Stürzl M Conference contribution Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution